Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics
- PMID: 38495549
- PMCID: PMC10941855
Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics
Abstract
Background: Onychomycosis is a fungal infection of the nail unit that affects a large patient population globally. Onychomycosis, or tinea unguium, has a benign chronic clinical course; however, it can cause complications in certain patient populations suffering from diabetes and peripheral vascular disease. As nails grow slowly, onychomycosis requires a lengthy treatment plan, and choosing appropriate treatments can be challenging. There are a variety of treatment modalities available for patients including topical, oral, laser, light therapy, procedures such as avulsion and matrixectomy, supplements, over-the-counter medication, and plasma therapy that can be used as monotherapy or in combination for patient satisfaction.
Objective: We sought to review treatment options for onychomycosis, taking into consideration the efficacy, side effect profiles, practicality of treatment (adherence), and costs to help healthcare providers offer ethically appropriate treatment regimens to their patients.
Methods: A literature search was conducted using electronic databases (PubMed, Embase, Medline, CINAHL, EBSCO) and textbooks, in addition to the clinical experiences of the authors and other practitioners in treating onychomycosis, and a summary of the findings are presented here.
Results: Although topical (efinaconazole, tavaborole, ciclopirox), oral (terbinafine, itraconazole), and laser (1064nm Nd:YAG lasers, both short-pulsed and Q-switched lasers, carbon dioxide lasers, and the diode 870, 930nm) are the current Food and Drug Administration (FDA)-approved treatments for onychomycosis, they are just a fraction of available treatment options. New and emerging therapies including new topical and oral medications, combination therapy, photodynamic light therapy, procedural, supplements, over-the-counter medication, and plasma therapy are discussed in our review.
Discussion: Onychomycosis has high reinfection and recurrence rates, and the treatment remains challenging as treatment selection involves ethical, evidence-based decision-making and consideration of each individual patient's needs, adherence, budget, the extent of quality of life discomfort, and aesthetic goals, independent of potential financial benefits to the clinicians.
Keywords: Onychomycosis; ethics; review; therapies; treatments.
Copyright © 2024. Matrix Medical Communications. All rights reserved.
Conflict of interest statement
DISCLOSURES: The authors report no conflicts of interest relevant to the content of this article.
Similar articles
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.J Cosmet Dermatol. 2021 Dec;20(12):3759-3781. doi: 10.1111/jocd.14537. Epub 2021 Nov 6. J Cosmet Dermatol. 2021. PMID: 34741573 Free PMC article. Review.
-
The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.J Clin Aesthet Dermatol. 2014 Jul;7(7):10-8. J Clin Aesthet Dermatol. 2014. PMID: 25053979 Free PMC article. Review.
-
Updated Perspectives on the Diagnosis and Management of Onychomycosis.Clin Cosmet Investig Dermatol. 2022 Sep 15;15:1933-1957. doi: 10.2147/CCID.S362635. eCollection 2022. Clin Cosmet Investig Dermatol. 2022. PMID: 36133401 Free PMC article. Review.
-
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S81-95. doi: 10.1067/mjd.2000.109069. J Am Acad Dermatol. 2000. PMID: 11051137
-
Onychomycosis in children - review on treatment and management strategies.J Dermatolog Treat. 2022 May;33(3):1213-1224. doi: 10.1080/09546634.2020.1810607. Epub 2020 Aug 26. J Dermatolog Treat. 2022. PMID: 32799713 Review.
Cited by
-
Diabetic Foot and Fungal Infections: Etiology and Management from a Dermatologic Perspective.J Fungi (Basel). 2024 Aug 15;10(8):577. doi: 10.3390/jof10080577. J Fungi (Basel). 2024. PMID: 39194903 Free PMC article. Review.
References
-
- Pariser DM Md. Efficacy and Safety of Onychomycosis Treatments: An Evidence-Based Overview. Semin Cutan Med Surg. 2015;34(3 Suppl):S46–S50. - PubMed
-
- Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853–867. - PubMed
-
- Asz-Sigall D, López-García L, Vega-Memije ME et al. HLA-DR6 association confers increased resistance to T. rubrum onychomycosis in Mexican Mestizos. Int J Dermatol. 2010;49(12):1406–1409. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials